(Q34503394)

2 August 2017

1 reference

title

Seven-transmembrane-spanning receptors and heart function (English)

1 reference

2 August 2017

main subject

transmembrane protein

0 references

Robert J Lefkowitz

1 reference

2 August 2017

Howard A Rockman

1 reference

2 August 2017

Walter J Koch

series ordinal

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 January 2002

1 reference

2 August 2017

1 reference

2 August 2017

volume

415

1 reference

2 August 2017

issue

6868

1 reference

2 August 2017

page(s)

206-212

1 reference

G protein beta gamma subunits.

2 August 2017

cites work

1 reference

7 January 2021

Cytoplasmic signaling pathways that regulate cardiac hypertrophy

1 reference

7 January 2021

G protein-coupled receptors. III. New roles for receptor kinases and beta-arrestins in receptor signaling and desensitization

1 reference

7 January 2021

G protein-coupled receptor kinases

1 reference

7 January 2021

The interaction of beta-arrestin with the AP-2 adaptor is required for the clustering of beta 2-adrenergic receptor into clathrin-coated pits

1 reference

7 January 2021

The proliferative and antiapoptotic effects of substance P are facilitated by formation of a beta -arrestin-dependent scaffolding complex

1 reference

7 January 2021

Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes

1 reference

7 January 2021

beta-arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2

1 reference

7 January 2021

Clathrin-coated vesicle formation and protein sorting: an integrated process

1 reference

7 January 2021

Activation and targeting of extracellular signal-regulated kinases by beta-arrestin scaffolds

1 reference

7 January 2021

Beta-arrestin 2: a receptor-regulated MAPK scaffold for the activation of JNK3

1 reference

7 January 2021

Regulation of receptor fate by ubiquitination of activated beta 2-adrenergic receptor and beta-arrestin

1 reference

7 January 2021

Stress pathways and heart failure

1 reference

7 January 2021

Cardiac overexpression of a G(q) inhibitor blocks induction of extracellular signal-regulated kinase and c-Jun NH(2)-terminal kinase activity in in vivo pressure overload

1 reference

7 January 2021

Important role of endogenous norepinephrine and epinephrine in the development of in vivo pressure-overload cardiac hypertrophy.

1 reference

7 January 2021

Gbetagamma-dependent phosphoinositide 3-kinase activation in hearts with in vivo pressure overload hypertrophy

1 reference

7 January 2021

Mechanism of beta-adrenergic receptor desensitization in cardiac hypertrophy is increased beta-adrenergic receptor kinase

1 reference

7 January 2021

Signaling in myocardial hypertrophy: life after calcineurin?

1 reference

7 January 2021

Transgenic Galphaq overexpression induces cardiac contractile failure in mice

1 reference

7 January 2021

Overexpression of angiotensin AT1 receptor transgene in the mouse myocardium produces a lethal phenotype associated with myocyte hyperplasia and heart block

1 reference

7 January 2021

Regulation of cardiac hypertrophy in vivo by the stress-activated protein kinases/c-Jun NH(2)-terminal kinases

1 reference

7 January 2021

Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy

1 reference

7 January 2021

Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy

1 reference

7 January 2021

Wall stress and patterns of hypertrophy in the human left ventricle

1 reference

7 January 2021

Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study

1 reference

7 January 2021

Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress.

1 reference

7 January 2021

Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure.

1 reference

7 January 2021

Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure

1 reference

7 January 2021

Why does the myocardium fail? Insights from basic science

1 reference

7 January 2021

The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure

1 reference

7 January 2021

Expression of beta-arrestins and beta-adrenergic receptor kinases in the failing human heart

1 reference

7 January 2021

Increase of the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart

1 reference

7 January 2021

Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A.

1 reference

7 January 2021

Dual modulation of cell survival and cell death by beta(2)-adrenergic signaling in adult mouse cardiac myocytes

1 reference

7 January 2021

Beta1-adrenoceptor gene variations: a role in idiopathic dilated cardiomyopathy?

1 reference

7 January 2021

The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure

1 reference

7 January 2021

Polymorphisms of the beta(2)-adrenergic receptor determine exercise capacity in patients with heart failure

1 reference

7 January 2021

Shattuck lecture--medical and societal consequences of the Human Genome Project

1 reference

7 January 2021

The effect of beta adrenergic blockade on patterns of urinary sodium excretion. Studies in normal subjects and in patients with heart disease

1 reference

7 January 2021

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

1 reference

7 January 2021

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group

1 reference

7 January 2021

Effect of carvedilol on survival in severe chronic heart failure

1 reference

7 January 2021

Cellular and functional defects in a mouse model of heart failure

1 reference

7 January 2021

Functional consequences of altering myocardial adrenergic receptor signaling

1 reference

7 January 2021

Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice.

1 reference

7 January 2021

Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor

1 reference

7 January 2021

Early and delayed consequences of beta(2)-adrenergic receptor overexpression in mouse hearts: critical role for expression level

1 reference

7 January 2021

Physiological consequences of beta-adrenergic receptor disruption

1 reference

7 January 2021

Targeted disruption of the beta2 adrenergic receptor gene

1 reference

7 January 2021

Opposing effects of beta(1)- and beta(2)-adrenergic receptors on cardiac myocyte apoptosis : role of a pertussis toxin-sensitive G protein

1 reference

7 January 2021

Low- and high-level transgenic expression of beta2-adrenergic receptors differentially affect cardiac hypertrophy and function in Galphaq-overexpressing mice

1 reference

7 January 2021

Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice

1 reference

7 January 2021

Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy

1 reference

7 January 2021

Restoration of beta-adrenergic signaling in failing cardiac ventricular myocytes via adenoviral-mediated gene transfer

1 reference

7 January 2021

Enhancement of cardiac function after adenoviral-mediated in vivo intracoronary beta2-adrenergic receptor gene delivery

1 reference

7 January 2021

Intracoronary adenovirus-mediated delivery and overexpression of the beta(2)-adrenergic receptor in the heart : prospects for molecular ventricular assistance

1 reference

7 January 2021

Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy

1 reference

7 January 2021

Cardiac-directed adenylyl cyclase expression improves heart function in murine cardiomyopathy

1 reference

7 January 2021

Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor

1 reference

7 January 2021

Essential role of beta-adrenergic receptor kinase 1 in cardiac development and function

1 reference

7 January 2021

Receptor-specific in vivo desensitization by the G protein-coupled receptor kinase-5 in transgenic mice

1 reference

7 January 2021

Control of myocardial contractile function by the level of beta-adrenergic receptor kinase 1 in gene-targeted mice

1 reference

7 January 2021

MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure

1 reference

7 January 2021

Defective beta-adrenergic receptor signaling precedes the development of dilated cardiomyopathy in transgenic mice with calsequestrin overexpression

1 reference

7 January 2021

Progression from hypertrophic to dilated cardiomyopathy in mice that express a mutant myosin transgene.

1 reference

7 January 2021

Cardiac beta ARK1 inhibition prolongs survival and augments beta blocker therapy in a mouse model of severe heart failure

1 reference

7 January 2021

Preservation of myocardial beta-adrenergic receptor signaling delays the development of heart failure after myocardial infarction

1 reference

7 January 2021

In vivo ventricular gene delivery of a beta-adrenergic receptor kinase inhibitor to the failing heart reverses cardiac dysfunction

1 reference

7 January 2021

Agonist-dependent recruitment of phosphoinositide 3-kinase to the membrane by beta-adrenergic receptor kinase 1. A role in receptor sequestration

1 reference

7 January 2021

Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by beta-adrenergic receptor stimulation and blockade

1 reference

7 January 2021

Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure

1 reference

7 January 2021

Identifiers

DOI

10.1038/415206A

1 reference

Dimensions Publication ID

2 August 2017

1021250868

0 references

1 reference